AMSTERDAM--(BUSINESS WIRE)--Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, today announced it has begun a ...
T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results